Our top pick for
OptimizeRx Corporation is a health information services business based in the US. OptimizeRx Corporation shares (OPRX) are listed on the NASDAQ and all prices are listed in US Dollars. OptimizeRx Corporation employs 70 staff and has a trailing 12-month revenue of around USD$34.3 million.
|52-week range||USD$6.5019 - USD$63.98|
|50-day moving average||USD$47.3673|
|200-day moving average||USD$28.6406|
|Wall St. target price||USD$61.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.041|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing OptimizeRx Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OptimizeRx Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
OptimizeRx Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 247x. In other words, OptimizeRx Corporation shares trade at around 247x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
OptimizeRx Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1267. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into OptimizeRx Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
OptimizeRx Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$298,779.
The EBITDA is a measure of a OptimizeRx Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$34.3 million|
|Gross profit TTM||USD$15.4 million|
|Return on assets TTM||-5.18%|
|Return on equity TTM||-12.64%|
|Market capitalisation||USD$924.6 million|
TTM: trailing 12 months
There are currently 1.0 million OptimizeRx Corporation shares held short by investors – that's known as OptimizeRx Corporation's "short interest". This figure is 4.1% up from 988,890 last month.
There are a few different ways that this level of interest in shorting OptimizeRx Corporation shares can be evaluated.
OptimizeRx Corporation's "short interest ratio" (SIR) is the quantity of OptimizeRx Corporation shares currently shorted divided by the average quantity of OptimizeRx Corporation shares traded daily (recently around 189255.88235294). OptimizeRx Corporation's SIR currently stands at 5.44. In other words for every 100,000 OptimizeRx Corporation shares traded daily on the market, roughly 5440 shares are currently held short.
However OptimizeRx Corporation's short interest can also be evaluated against the total number of OptimizeRx Corporation shares, or, against the total number of tradable OptimizeRx Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OptimizeRx Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 OptimizeRx Corporation shares in existence, roughly 70 shares are currently held short) or 0.0706% of the tradable shares (for every 100,000 tradable OptimizeRx Corporation shares, roughly 71 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against OptimizeRx Corporation.
Find out more about how you can short OptimizeRx Corporation stock.
We're not expecting OptimizeRx Corporation to pay a dividend over the next 12 months.
OptimizeRx Corporation's shares were split on a 1:3 basis on 14 May 2018. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OptimizeRx Corporation shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for OptimizeRx Corporation shares which in turn could have impacted OptimizeRx Corporation's share price.
Over the last 12 months, OptimizeRx Corporation's shares have ranged in value from as little as $6.5019 up to $63.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OptimizeRx Corporation's is 0.6435. This would suggest that OptimizeRx Corporation's shares are less volatile than average (for this exchange).
OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare. Its cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, and critical clinical information; and network consists of electronic health record company platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and clinical messaging services. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.